key: cord-0007545-uu85cuq0 authors: Almeida, Sherri-Lynne title: Trending Now: Re-Emerging Infectious Disease Update date: 2015-03-10 journal: J Emerg Nurs DOI: 10.1016/j.jen.2015.01.001 sha: 6646b545930bba5280cfe84801fc6640b9c1144e doc_id: 7545 cord_uid: uu85cuq0 nan Author: Sherri-Lynne Almeida, DrPH, MSN, MEd, RN, CEN, FAEN, Houston, TX D espite advances in medical research and disease management during the 20th century, infectious diseases remain among the leading causes of death worldwide for 3 reasons: emergence of new infectious diseases, re-emergence of old infectious diseases, and persistence of intractable infectious diseases. What is an emerging or re-emerging infectious disease? It is an "infection that has newly appeared in a population or has existed but is rapidly increasing in incidence or geographic range." 1 If the disease was unknown in the location before, the disease is considered to be emerging. However, if the disease had been present at the location in the past and was considered eradicated or controlled, the disease is considered to be re-emerging. 1 Emerging infectious diseases are caused by new, or previously unrecognized, micro-organisms. Multiple factors contribute to the emergence of new infectious diseases. They include the increasing growth and mobility of the world's population, overcrowding in cities with poor sanitation, massive food preparation and international distribution, unsanitary food preparation, exposure of humans to disease vectors and reservoirs, and ecological changes that alter the composition and size of insect vectors and animal reservoirs. Severe acute respiratory syndrome (SARS) was the first emerging infectious disease of the 21st century. Re-emerging infectious diseases are caused by infectious agents that have been known for some time, have fallen to such low levels that they were no longer considered public health problems, and are now exhibiting an upward trend in incidence or prevalence worldwide. Re-emergence is caused by some of the same factors that cause newly emerging infectious diseases. Re-emergences or at least cyclical resurgences of some diseases may also be climate related. For example, the El Niño/Southern Oscillation phenomenon is associated with resurgences of cholera and malaria. 2 As we observe new pathogens emerge, we are also witnessing a re-emergence of some old infectious diseases. In addition to the factors previously mentioned, human behavior is a major factor in re-emergence. Increased use of antimicrobial drugs has resulted in the development of resistant pathogens (eg, tuberculosis), allowing many diseases that were treatable with medications to recur. Decreased compliance with vaccination has also resulted in the re-emergence of diseases such as measles and pertussis. Measles, also known as rubeola, is a highly contagious disease that is caused by a virus and can have serious consequences. In 1980, before widespread vaccination, measles caused an estimated 2.6 million deaths each year worldwide. 3 In 2000, measles was declared eliminated from the United States (ie, continuous disease transmission was absent for more than 12 months). 4 Today, most of the measles cases in the US are brought here by international travelers because measles continues to be a common disease in many parts of the world. Unvaccinated travelers transmit the disease when they are exposed to others who are not vaccinated. In 2014, the US experienced a record number of measles cases (603 cases as of October 31, 2014). 4 According to the Centers for Disease Control and Prevention (CDC), this is the highest number of cases in the US since measles was declared eliminated. Case classification (Table 1 ) is a set of uniform public health surveillance criteria used to define reportable diseases, such as measles. These criteria enable public health officials to classify and count cases consistently across reporting jurisdictions. These criteria are not for use by health care providers in determining how to meet an individual patient's health care needs. Measles, an acute viral respiratory illness, is characterized by a prodrome of fever, malaise, and the three "C"s-cough, coryza, and conjunctivitis. Koplik spots, found on the buccal mucosa, are pathognomonic for the disease. A generalized maculopapular rash usually appears about 14 days after exposure and progresses in a cephalocaudal direction, affecting the head, trunk, and lower extremities. The incubation period ranges from 7 to 21 days, and patients are considered contagious 4 days prior to the appearance of the rash until 4 days after the appearance of the rash. The clinical course in an uncomplicated case of measles, from late prodrome to resolution of fever and rash, lasts 7 to 10 days. Cough may be the final symptom to appear. Common complications include otitis media, bronchopneumonia, laryngotracheobronchitis, and diarrhea. According to the CDC, acute encephalitis will develop in 1 out of every 1000 measles cases, often resulting in permanent brain damage. Of each thousand children who become infected, 1 to 2 will die from respiratory and neurologic complications. A rare but fatal complication is subacute sclerosing panencephalitis. This degenerative disease of the central nervous system is characterized by behavioral and intellectual deterioration and seizures that can develop up to 7 to 10 years after the original infection. 4 Unvaccinated young children are at highest risk for measles and its complications. Additionally, infants and children younger than 5 years, unvaccinated pregnant women, and adults with compromised immune systems are high risk for severe illness and complications. This contagious virus is transmitted by coughing and sneezing, close personal contact, or direct contact with infected nasal and/or throat secretions. The virus can remain infectious on surfaces and in the air up to 2 hours after an infected person leaves the area. No specific treatment exists. Care is supportive and focused on the relief of developing symptoms. Vaccination is the most effective method for the prevention of measles. The CDC recommends routine childhood immunization with measles-mumps-rubella (MMR) vaccine starting with the first dose at 12 through 15 months of age and the second dose at 4 through 6 years of age, or at least 28 days after the first dose. Acceptable presumptive evidence of immunity against measles includes at least one of the following: written documentation of adequate vaccination; one or more doses of a measlescontaining vaccine administered on or after the first birthday for preschool-aged children and adults not at high risk; two doses of measles-containing vaccine for school-aged children and adults at high risk, including college students, health care personnel, and international travelers; laboratory evidence of immunity; or laboratory confirmation of measles or birth in the US before 1957. Adults with no previous evidence of immunity require at least one dose of MMR. People exposed to measles who cannot readily show that they have evidence of immunity against measles should be offered postexposure prophylaxis or be excluded from the setting (such as a school, hospital, or child care). MMR vaccine, if administered within 72 hours of the initial measles exposure, or immunoglobulin, if administered within 6 days of exposure, may provide some In the absence of a more likely diagnosis, an illness that meets the clinical description with: No epidemiologic linkage to a laboratory-confirmed measles case; and • Noncontributory or no measles laboratory testing An acute febrile rash illness a with: • Isolation of measles virus b from a clinical specimen; or • Detection of measles-virus specific nucleic acid b from a clinical specimen using polymerase chain reaction; or • Immunoglobulin G seroconversion b or a significant rise in measles immunoglobulin G antibody b using any evaluated and validated method; or Pertussis is a highly contagious bacterial disease of the respiratory tract caused by Bordetella pertussis. In the prevaccination era, pertussis was a leading cause of infant death. Pertussis is an endemic disease in the US, with frequent outbreaks and peaks in disease every 3 to 5 years. 4 Reported cases of pertussis rose to 48,277 in 2012, the most reported since 1955, and 20 pertussis-related deaths occurred. 4 The rate of pertussis among infants exceeded that of all other age groups, with the majority of deaths occurring in infants younger than 3 months. As of August 16, 2014, a total of 17,325 cases had been reported to the CDC for the year-a 30% increase compared with the same period in 2013. Pertussis is a reportable disease in the US, which includes reporting of both probable and confirmed cases. The case classification criteria for pertussis ( Table 2) is inclusive of the clinical case definition. Clinicians should consider the diagnosis of pertussis for patients who have a cough lasting longer than 2 weeks with one of the following symptoms: paroxysms of coughing, inspiratory "whoop," or posttussive vomiting, or in infants younger than 1 year, apnea with or without cyanosis. Pertussis is a respiratory tract infection characterized by a paroxysmal cough. The clinical course of the illness is divided into 3 stages: catarrhal, paroxysmal, and convalescent. Stage 1 (catarrhal) is characterized by nasal congestion, rhinorrhea, sneezing, low-grade fever, tearing, and conjunctival suffusion. In stage 2, patients have paroxysms of intense coughing lasting up to several minutes. o Acute cough illness of any duration with at least one of the following signs or symptoms: These episodes of coughing may occur more frequently at night. They usually increase in frequency and severity as the disease progresses. Posttusive vomiting and facial reddening with coughing is not uncommon. The coughing can be so severe that broken blood vessels in the eyes and bruising on the face may occur (Figure) . The characteristic whoop may be absent in a mild case if the patient was vaccinated. Pertussis can cause serious life-threatening complications in infants and young children who are not fully vaccinated. CDC data indicate that about half of the infants younger than 1 year who contract pertussis are hospitalized. Of those who are hospitalized, 67% will have apnea and 1.6% will die. 5 Persons of all ages may experience complications; however, if they have previously been vaccinated, the complications are usually less severe. Fewer than 5% of teens and adults with pertussis are hospitalized. 5 Pertussis, which occurs only in humans, is spread from person to person and is very contagious. It is usually spread by coughing or sneezing while in close contact with others, who then breathe in the pertussis bacteria. Many infants who contract pertussis are infected by older siblings, parents, or caregivers who may not know they have the disease. 6 Symptoms of pertussis usually develop within 5 to 10 days after exposure but may be delayed for as long as 3 weeks. Early treatment of pertussis is essential. The earlier treatment begins, the less severe the course may be, especially in infants. If treatment for pertussis begins during the first 1 to 2 weeks before coughing paroxysms occur, symptoms may be lessened. Clinicians should strongly consider initiating treatment prior to obtaining test results if the clinical history is strongly suggestive of pertussis or if the patient is at risk for severe or complicated disease (eg, infants). If the patient is diagnosed late, antibiotics will not alter the course of the illness. Even without antibiotics, the patient should no longer be spreading pertussis. Persons with pertussis are infectious from the beginning of the catarrhal stage (marked by a runny nose, sneezing, a low-grade fever, and symptoms of the common cold) through the third week after the onset of paroxysms (multiple, rapid coughs) or until 5 days after the start of effective antimicrobial treatment. 7 Vaccination is the best prevention against pertussis. The recommended pertussis vaccine for infants and children is DTaP, which provides protection against diphtheria, tetanus, and pertussis. Because protection fades over time, a booster DTaP is suggested for teens and adults. 7 Enterovirus D68 (EV-D68) is one of more than 100 nonpolio enteroviruses. According to the CDC, nonpolio enteroviruses are very common and cause about 10 to 15 million infections in the US each year. In addition to EV-D68, other examples of nonpolio enteroviruses include coxsackievirus A, coxsackievirus B, and echoviruses. 8 Since 1962, when it was first identified in California, EV-D68 has rarely been reported in the US. The National Enterovirus Surveillance System received reports of 79 EV-D68 cases during 2009-2013, and small clusters of cases associated with respiratory illness were reported during 2009-2010. 9 In 2014, a nationwide outbreak of the disease occurred in the US, and as of November 12, 2014, a total of 1116 people in 47 states and the District of Columbia with respiratory illness were confirmed positive for EV-D68. 9 Nonpolio enterovirus can infect anyone; however, infants, children, and teenagers are more likely to become infected and get sick. Overall, the majority of people infected with nonpolio enteroviruses do not exhibit symptoms or have only mild symptoms. People with compromised immune systems and infants are at greater risk for serious illness, such as the development of myocarditis, pericarditis, encephalitis, or paralysis. EV-D68 can cause mild to severe respiratory illness. Symptoms of mild illness may include fever, runny nose, sneezing, cough, skin rash, and body/muscle aches. 10 Persons with pre-existing conditions, such as asthma or other respiratory diseases, may be especially prone to severe infections from EV-D68 and may experience difficulty breathing or wheezing. In 2014, all confirmed cased of EV-D68 infection were among children, many of whom had asthma or a history of wheezing. Specimens submitted for testing from 12 patients who died tested positive for the EV-D68 virus. 8 Broken blood vessels in the eyes and bruising on the face caused by severe coughing. Centers for Disease Control and Prevention. This virus is transmitted from person to person through coughing and sneezing, close personal contact or direct contact with infected nasal and/or throat secretions, or by touching a contaminated surface. Diagnosis of EV-D68 is confirmed by laboratory examination. The CDC recommends that clinicians consider testing for patients with severe respiratory illness when another cause is unclear. 8 No specific treatment exists for people infected with EV-D68. Patient management includes supportive care and treatment specific to any complications that may develop. The best method of self-protection is hand and environmental hygiene. The best defense against the resurgence of long-standing infectious diseases and the emergence of new infectious diseases is multifactorial. A well-coordinated, well-prepared, and well-equipped public health system is essential, necessitating partnerships and collaboration among public health agencies, hospitals, clinicians, and laboratorians. Timely recognition of emerging infections will require early warning systems for rapid problem detection and prompt investigation and control to avert a public health crisis. A worldwide approach is crucial with a focus on strengthened response capacity and expanded international collaboration and communication. Nations must commit to the provision of adequate resources to address underlying socioeconomic factors. None of this will be possible without education. As we learn what poses a threat, we can alter our behavior to reduce the risk. Although multiple high-tech solutions are available to reduce the spread of infectious diseases, it is most important to remember hygiene basics and that we each play a significant role in reducing infections. What are you doing to reduce the spread of infectious diseases? Factors in the emergence of infectious diseases El Niño and health Centers for Disease 695 Control and Prevention, US Dept of Health and Human Services Transmission of Bordetella pertussis to young infants Centers for Disease Control and Prevention. National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention. Enterovirus D68 in the United States Clusters of acute respiratory illness associated with human enterovirus 68-Asia, Europe, and United States Enterovirus (nonpoliovirus) and parechovirus infections (group A and B coxsackieviruses, echoviruses, numbered enteroviruses, and human parechoviruses)-clinical manifestations